In summary, our study highlights the HDAC inhibitor M344 as a novel and efficacious potential treatment modality for the pediatric cancer NB, particularly addressing the need for treatments that combine efficacy with reduced toxicity and long-lasting effects. Here, HDAC9 is linked to cancer.